IL-NIELSENIQ
21.7.2022 13:02:04 CEST | Business Wire | Press release
NielsenIQ is pleased to announce the 2022 recipients of the seventh annual NielsenIQ BASES Design Impact Awards for the consumer-packaged goods (CPG) industry. The global competition recognizes and celebrates best-in-class package redesigns, and the business impacts they make for their companies. This year’s winners include brands that delivered innovative and creative packaging with design concepts that reflected brand vision while supporting the shopper journey.
Sixty brands submitted package redesigns and the NielsenIQ BASES team used the company’s proprietary Retail Measurement Sales (RMS) data to identify which brands demonstrated an increase in sales after the launch of the updated package designs. In addition to evaluating RMS data, NielsenIQ conducted a behavioral survey of 15,000 shoppers to assess individual entries across the shopper journey. Each product was evaluated to determine if it presented a visually appealing, easily identifiable package that allowed consumers to find the product on shelves and engage them to purchase the item. The results unveiled 10 winners across various CPG categories with excellent designs and a measurable increase in sales.
“Our team is thrilled to support and promote inspired brands who deliver fresh, beautifully designed packages that stimulate brand growth and financial successes,” said Andrea Fraboni, Vice President & Global Leader of BASES Design Solutions at NielsenIQ. “This year’s winners embody how effective redesigned packaging can help transform and elevate the bottom line of a brand. These companies did it right and we’re excited to showcase their outstanding accomplishments.”
The winners of the 2022 NielsenIQ BASES Design Impact Award* are:
- L’usine Sliced Multigrain Bread (Parent Company: Almarai; Country: Saudi Arabia)
- Coors Light Beer (Parent Company: Molson Coors Beverage Company; Design Agency: Soulsight; Country: United States)
- Brooke's Oros Beverages (Parent Company: Tiger Brands; Design Agency: Just Design; Country: South Africa)
- Cadbury Old Gold Chocolate (Parent Company: Mondelez International; Design Agency: Bulletproof; Country: Australia)
- Lucozade Energy Drink (Parent Company: Suntory; Country: United Kingdom)
- Nescafé Artesano Coffee (Parent Company: Nestlé; Country: Colombia)
- SSENSE Herbal Tea (Parent Company: SSENSE; Design Agency: Pigeon; Country: Canada)
- Turin Chocolate (Parent Company: Mars; Country: Mexico)
- Speed Stick & Lady Speed Stick (Parent Company: Colgate-Palmolive; Design Agency: Dragon Rouge BZ; Country: Mexico)
- Lay's Potato Chips (Parent Company: PepsiCo; Design Agency: PEP Global Design Team; Country: South Africa)
Learn more about our package design research solutions, the NielsenIQ BASES Design Impact Award, and learnings from this year’s winners by visiting the BASES Design Impact Award web page.
*All products and company names are trademarks of their respective holders. No affiliation or endorsement is expressed or implied.
About NielsenIQ
NielsenIQ, a global information services company, delivers the gold standard in consumer and retail measurement, through the most connected, complete, and actionable understanding of the evolving global, omnichannel consumer. NielsenIQ is the source of confidence for the industries we serve and the pioneer defining the next century of consumer and retail measurement. Our data, connected insights, and predictive analytics optimize the performance of CPG and retail companies, bringing them closer to the communities they serve and helping to power their growth.
NielsenIQ, an Advent International portfolio company, has operations in 90+ markets, covering more than 90% of the world’s population. For more information, visit NielsenIQ.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220721005158/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
IEO and Laife Reply Join Forces to Digitalise the Biobank Through Artificial Intelligence10.2.2026 10:00:00 CET | Press release
The two partners launch “Bianca”, the first large-scale digitalisation initiative in Italy focused on histopathological samples, aimed at training AI algorithms to support pathologists’ diagnostic activities. The Pathology Division of the European Institute of Oncology (IEO) and Laife Reply, the Reply Group company specialised in AI and Big Data solutions for the healthcare sector, have entered into a collaboration to develop Bianca, the first project in Italy aimed at creating an AI-based digital biobank designed as an integral part of clinical diagnostic practice. The initiative is part of a broader technological innovation journey that structurally integrates research and development into routine diagnostic processes in pathology, transforming the traditional histopathological sample workflow into an end-to-end digital ecosystem. The complete digitalisation of histopathological and molecular diagnostic workflows aims to make analysis more efficient, scalable and reproducible, laying
OPEX® Corporation Introduces the Velo™ Series of Premium Desktop and High Production Document Scanners10.2.2026 10:00:00 CET | Press release
OPEX® Corporation, a global leader in Next Generation Automation providing innovative solutions for warehouse, document and mail automation, has announced the launch of its Velo™ Series powered by InoTec, a new class of premium desktop and free standing high production scanners. The OPEX Velo scanners are engineered to deliver exceptional performance, reliability and image quality and offer industry-standard TWAIN/ISIS connectivity to help simplify deployment into existing capture environments. These state-of-the-art scanners are ideal for service bureaus, government agencies, healthcare providers and enterprise capture operations. “The Velo Series powered by InoTec introduces an entirely new class of scanners to the OPEX portfolio, expanding the options available to both our current customers and organizations considering OPEX for the first time,” said Dann Worrell, President, Document and Mail Automation, OPEX. “By broadening our offerings, we can better align the right solution with
New ZOLL Zenix Monitor/Defibrillator Receives MDR Approval10.2.2026 10:00:00 CET | Press release
ZOLL®, an Asahi Kasei company that manufactures medical devices and related software solutions, announced today that Zenix®, the company’s most clinically advanced and easy-to-use professional monitor/defibrillator, is approved under the European Union (EU) Medical Device Regulation 2017/745, commonly referred to as EU MDR. The Zenix monitor/defibrillator is a groundbreaking device that redefines efficiency, clarity, and intelligence in both EMS and hospital settings. Built from years of feedback from customers, Zenix combines intuitive design with powerful functionality to enhance patient care and automate workflows for ease-of-use. Featuring a large, durable touchscreen, Zenix provides critical information when it’s needed. With on-the-fly customization, healthcare professionals can make real-time adjustments, helping them stay in control during high-pressure situations. Equipped with ZOLL’s innovative Real BVM Help® and exclusive Real CPR Help® technology, Zenix gives healthcare pro
Expereo Elevates expereoOne with New Digital Case Management Capabilities, Delivering Faster, Clearer and More Predictable Service Resolution10.2.2026 10:00:00 CET | Press release
Expereo is redefining what’s possible for global enterprises at CiscoLive Amsterdam with the launch of its enhanced Digital Case Management (DCM) capability in expereoOne. As the world-leading managed Network as a Service (NaaS) provider, Expereo is putting customers firmly in control - slashing resolution times, cutting through operational noise and ensuring everyone is aligned every step of the way. With DCM, service issues are no longer bottlenecks: instead, enterprises experience swift, transparent outcomes, with every stakeholder empowered through a single, real-time view of progress. DCM is designed around a simple objective: enable enterprises to resolve issues faster, with greater clarity and full control, through a fully digital, software-first workflow inside expereoOne. Customers can create, manage and track cases end-to-end within a single platform, ensuring predictable, consistent and aligned service experiences across their global network footprint. Unified, digital-first
U.S. Food and Drug Administration Accepts New Drug Application and Grants Priority Review for Takeda’s Oveporexton (TAK-861) as a Potential First-in-Class Therapy for Narcolepsy Type 110.2.2026 09:15:00 CET | Press release
This FDA Acceptance is a Milestone for People Living with Narcolepsy Type 1 Who Need New and Different Treatment OptionsOveporexton is an Orexin Agonist Designed to Restore Orexin Signaling and Address the Underlying Orexin Deficiency that Causes Narcolepsy Type 1The Prescription Drug User Fee Act (PDUFA) Target Action Date is the Third Quarter of this Calendar Year Takeda (TSE:4502/NYSE:TAK) today announced that the U.S. Food and Drug Administration (FDA) accepted its New Drug Application (NDA) and granted Priority Review for oveporexton (TAK-861) for the treatment of narcolepsy type 1 (NT1). Oveporexton is an investigational oral orexin receptor 2 (OX2R)-selective agonist designed to address the underlying orexin deficiency that causes NT1 by restoring orexin signaling. The FDA has set a Prescription Drug User Fee Act (PDUFA) goal date in the third quarter of this calendar year. Takeda remains on track to potentially bring the first approved orexin agonist treatment to people living
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
